Medicare AdvantageCoverageMedium impact
Laparoscopic, Percutaneous, and Transcervical Techniques for Uterine Fibroid Myolysis
Blue Cross Blue Shield of Rhode Island·RI · OB-GYN·Physician / Facility
Effective date
Jan 1, 2022
We identified it
Jun 19, 2026
Summary
Effective January 1, 2022, BCBSRI now considers laparoscopic or transcervical radiofrequency ablation for symptomatic uterine fibroids (CPT 58674) medically necessary when specific criteria are met. This coverage change applies to both Medicare Advantage and commercial plans.
Action Required
Billing team must verify BCBSRI medical policy criteria are met before billing CPT 58674 for uterine fibroid radiofrequency ablation. Review the referenced medical policy guidelines to ensure proper documentation supports medical necessity. Claims may be denied if criteria are not satisfied.